Shopping for tires has a lot in common with picking cybersecurity stocks.
Here’s how I came up with this line of thought.
My wife needs new tires for her luxury SUV, an Infiniti FX35, and they need to perform in all sorts of weather.
See, we live up in the hills, and she drives to work along narrow roads with dangerous, hairpin curves.
Some mornings the fog is so thick that the roads get slick. In the rainy season, these roads get even slicker. If she skidded and went over the side, she could easily plunge 200 feet to the bottom of a canyon.
In other words, we are willing to pay extra to get excellent performance in all conditions.
You should take the same approach to investing in the growth field of cybersecurity.
While this is a vital industry, many of the stocks in this sector are choppy and news driven.
That makes it easy to lose money on those kinds of trades if you get the timing wrong.
But I have uncovered what I believe is a great “all-weather” cybersecurity leader. This is the kind of stock that will keep you on the road to wealth even in the stormiest of conditions.
It often takes 10 years and costs up to $3 billion to get a new drug approved and on the market in the United States.
In other words, putting together a new treatment is expensive in time and money.
So any firm that can help Big Pharma and tiny biotechs alike shave years and hundreds of millions off the cost of drug research will soon be printing money for both itself and its investors.
That alone makes me ready to recommend the medical research company I’m sharing with you today.
But there’s more here.
A lot more…
Fact is, this is a great “pick and shovel” play on one of the fastest growing markets in the world today – legal cannabis. Turns out, this firm has quietly set itself up as a marijuana testing and analysis firm.
Today, I’ll show you why that’s great for the whole cannabis sector.
And how it will help this stock crush the overall market – and keep growing for years to come.
I’m talking about a federal cannabis reform bill getting through the House Judiciary Committee during Republican control of Congress.
And it’s all set to go down Thursday, when the committee will decide whether to green-light the Medical Cannabis Research Act. The bill would mandate that the federal government provide more licenses to grow marijuana used in scientific research.